Sequential rapid oral desensitization to valsartan: a case report

Main Article Content

Scott T. Benken David J. Silva Christen Vagts Andrea A. Pappalardo

Abstract

The literature surrounding oral antihypertensive desensitization procedures is limited. Desensitization is a therapeutic option for many medications but little information exists for anti-hypertensives, and no information exists for valsartan.


Case description:


A 55-year-old man developed hypersensitivity reactions to several antihypertensive medications, including valsartan. Multiple attempts were made trialing numerous anti-hypertensives.  A 17-step rapid sequential oral desensitization procedure to valsartan was performed in this patient with successful tolerance and an absence of hypersensitivity reactions which led to adherence and chronic blood pressure control.


Conclusion:


To our knowledge this is the first report of valsartan desensitization. This successful intervention allowed for the patient to continue taking an essential antihypertensive medication necessary for optimal blood pressure control. The intention of this report is to help guide the management of complex patients who require desensitization to valsartan and to other antihypertensives in the future.

Keywords: Desensitization, Valsartan, Allergy, hypersensitivity reaction, angiotensin receptor blocker

Article Details

How to Cite
BENKEN, Scott T. et al. Sequential rapid oral desensitization to valsartan: a case report. Medical Research Archives, [S.l.], v. 7, n. 12, dec. 2019. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2019>. Date accessed: 29 mar. 2024. doi: https://doi.org/10.18103/mra.v7i12.2019.
Section
Research Articles

References

1. Castells, M. Desensitization for drug allergy. Current Opinion in Allergy and Clinical Immunology 2006; 6(6): 476–481.

2. Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, et al. General considerations on rapid desensitization for drug hypersensitivity – a consensus statement. Allergy 2010; 65:1357–1366.

3. Justiz Vaillant AA, Zito PM. Hypersensitivity Reactions, Immediate. StatPearls [Internet]; 2018 Available at https://www.ncbi.nlm.nih.gov/books/NBK513315/. Accessed February 12, 2019.

4. Vardakas KZ, Kalimeris GD, Triarides NA, Falagas ME. An update on adverse drug reactions related to β-lactam antibiotics. Expert Opin Drug Saf 2018; 17(5):499-508.

5. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702-12.

6. Shtessel M, Tversky J. Reliability of allergy skin testing. Ann Allergy Asthma Immunol. 2018;120(1):80-83.

7. Li X, Lu Y, Jin Y, Son JK, Lee SH, Chang HW. Curcumin inhibits the activation of immunoglobulin e-mediated mast cells and passive systemic anaphylaxis in mice by reducing serum eicosanoid and histamine levels. Biomol Ther (Seoul). 2014;22(1):27-34.

8. Li J, Fernando SL. Successful rapid desensitization to hydrochlorothiazide. Ann Allergy Asthma Immunol. 2013;110(4):307-8.

9. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published online November 13, 2017]. Hypertension. doi:10.1161/HYP.0000000000000065

10. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. doi:10.1001/jama.2013.284427.

11. Chastain DB, Hutzley VJ, Parekh J, et al. Antimicrobial Desensitization: A Review of Published Protocols. Pharmacy. 2019; 7(3):112. https://doi.org/10.3390/pharmacy7030112